Glenview Capital Management

Quanta is a medical devices company that develops advanced haemodialysis systems for use in the home and clinic. Quanta is focused on the commercialisation and ongoing development of SC+, an innovative cartridge-based haemodialysis system. SC+ is a high performance, compact haemodialysis system providing clinical efficacy by utilising typical flow rates of traditional in-centre machines. SC+ supports the entire ‘Continuum of Care’ for dialysis patients, from nurse-assisted treatment through self-care in centre to home haemodialysis. Their system facilitates the seamless transition between treatment modalities providing the best tool to enable flexibility for patients, and treatment options for physicians.

Detect they build tools that empower people to understand their health.

Limber Health operates a healthcare platform that integrates digital technology with in-clinic musculoskeletal (MSK) care. Designed by physical therapists and physicians, the platform provides tools for remote therapeutic monitoring, home exercise programs, outcomes collection, and care navigation, facilitating a hybrid model of care that combines in-person visits with digital support. Clinically validated through research at Mayo Clinic, Limber Health has been recognized for its impactful technology in the field of rehabilitation. The platform aims to enhance patient care by allowing providers to extend their services beyond the clinic, ensuring that patients receive comprehensive support tailored to their needs.

Quanta is a medical devices company that develops advanced haemodialysis systems for use in the home and clinic. Quanta is focused on the commercialisation and ongoing development of SC+, an innovative cartridge-based haemodialysis system. SC+ is a high performance, compact haemodialysis system providing clinical efficacy by utilising typical flow rates of traditional in-centre machines. SC+ supports the entire ‘Continuum of Care’ for dialysis patients, from nurse-assisted treatment through self-care in centre to home haemodialysis. Their system facilitates the seamless transition between treatment modalities providing the best tool to enable flexibility for patients, and treatment options for physicians.

Quantum-Si is focused on revolutionizing the growing field of proteomics. The company’s suite of technologies are powered by a first-of-its-kind semiconductor chip designed to enable single-molecule next-generation protein sequencing and genomics, and digitize proteomic research in order to advance drug discovery and diagnostics beyond what has been possible with DNA sequencing.

Identifeye is creating prediction models that combine multiple retinal imaging modalities with expert annotations to create comprehensive and non-invasive health assessments. Identifeye Health is a part of the 4Catalyzer accelerator, which is dedicated to improving patient care globally. It has offices in Guilford, Connecticut, New York City, and Palo Alto, California.

Butterfly Network develops innovative medical imaging devices designed to enhance point-of-care ultrasound programs in hospitals and healthcare organizations. Founded in 2011 and based in Guilford, Connecticut, the company has created the first handheld, single-probe whole-body ultrasound system, utilizing its patented Ultrasound-on-Chip technology. This compact device enables healthcare professionals to perform diagnostic imaging across various medical fields, including cardiology, urology, and obstetrics, all while integrating seamlessly into clinical workflows through mobile applications. Butterfly Network aims to democratize access to medical imaging, particularly for the 4.7 billion individuals globally who currently lack access to ultrasound, thereby promoting early detection and remote management of health conditions.

Calypso Medical Technologies is a Seattle-based, privately held medical device company. The Company's proprietary tumor localization system utilizes miniaturized implanted devices (Beacon® electromagnetic transponders) to continuously, accurately and objectively track the location of tumors for improved accuracy and management of radiation therapy delivery. The technology is designed for body-wide cancers commonly treated with radiation therapy. The products are FDA 510(k) cleared for use in the prostate and post-operative prostatic bed. The Company has strategic relationships with Varian Medical Systems, Siemens Medical Systems, Elekta Corporation, and Philips Medical.